Caris Unveils AI for Ovarian Cancer Treatment

Caris Life Sciences introduced a new AI-driven signature to predict early platinum resistance in high-grade serous ovarian cancer ^[1][3]. This tool provides molecular insights intended to help clinicians personalize chemotherapy treatment plans ^[1][2]. While many patients initially respond to platinum-based therapy, resistance remains a significant clinical challenge ^[3]. The tool identifies patients likely to experience early disease progression ^[1]. By utilizing extensive genomic and transcriptomic data, Caris AI Insights aims to optimize therapeutic decision-making ^[2][3]. This advancement represents a shift toward precision medicine in oncology ^[1].